Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Ovarian Neoplasms | 27 | 2024 | 4904 | 3.710 |
Why?
|
Terminal Care | 26 | 2024 | 1769 | 3.230 |
Why?
|
Genital Neoplasms, Female | 7 | 2024 | 534 | 1.830 |
Why?
|
Hospice Care | 14 | 2023 | 678 | 1.660 |
Why?
|
Peritoneal Neoplasms | 3 | 2024 | 706 | 1.640 |
Why?
|
Caregivers | 16 | 2024 | 2303 | 1.430 |
Why?
|
Quality of Life | 25 | 2024 | 13476 | 1.150 |
Why?
|
Neoplasms | 33 | 2024 | 22350 | 1.130 |
Why?
|
Fatigue | 5 | 2024 | 1555 | 1.040 |
Why?
|
Femoracetabular Impingement | 2 | 2020 | 180 | 1.000 |
Why?
|
Patient Preference | 6 | 2022 | 946 | 0.930 |
Why?
|
Endometrial Neoplasms | 5 | 2022 | 1380 | 0.900 |
Why?
|
Neoplasms, Glandular and Epithelial | 3 | 2018 | 488 | 0.890 |
Why?
|
Telemedicine | 5 | 2024 | 3111 | 0.840 |
Why?
|
Exercise Therapy | 3 | 2020 | 938 | 0.800 |
Why?
|
Terminally Ill | 6 | 2016 | 240 | 0.800 |
Why?
|
Analgesics, Opioid | 4 | 2023 | 3837 | 0.790 |
Why?
|
Rosa | 1 | 2021 | 8 | 0.780 |
Why?
|
Uterine Cervical Neoplasms | 7 | 2021 | 2039 | 0.780 |
Why?
|
Neoadjuvant Therapy | 6 | 2018 | 2902 | 0.730 |
Why?
|
Medical History Taking | 2 | 2021 | 779 | 0.700 |
Why?
|
Antineoplastic Agents | 8 | 2022 | 13643 | 0.680 |
Why?
|
Hip | 1 | 2021 | 251 | 0.670 |
Why?
|
Feasibility Studies | 4 | 2024 | 5306 | 0.660 |
Why?
|
Hospices | 4 | 2017 | 245 | 0.650 |
Why?
|
Sexual Dysfunctions, Psychological | 2 | 2019 | 193 | 0.650 |
Why?
|
Neoplasm Recurrence, Local | 8 | 2022 | 9404 | 0.650 |
Why?
|
Platinum Compounds | 1 | 2019 | 94 | 0.630 |
Why?
|
Patient-Centered Care | 4 | 2024 | 1445 | 0.610 |
Why?
|
Focus Groups | 2 | 2024 | 1459 | 0.600 |
Why?
|
Genetic Testing | 2 | 2022 | 3591 | 0.590 |
Why?
|
Palliative Care | 10 | 2023 | 3640 | 0.560 |
Why?
|
Arthralgia | 1 | 2021 | 459 | 0.550 |
Why?
|
Advance Care Planning | 7 | 2024 | 698 | 0.540 |
Why?
|
Genetic Counseling | 1 | 2020 | 634 | 0.540 |
Why?
|
Allied Health Personnel | 1 | 2018 | 156 | 0.530 |
Why?
|
Pilot Projects | 7 | 2024 | 8728 | 0.520 |
Why?
|
Female | 90 | 2024 | 396520 | 0.510 |
Why?
|
Insurance, Health | 5 | 2022 | 2520 | 0.500 |
Why?
|
Sports | 1 | 2021 | 701 | 0.490 |
Why?
|
Cost of Illness | 2 | 2022 | 1949 | 0.490 |
Why?
|
Humans | 116 | 2024 | 766766 | 0.480 |
Why?
|
Bereavement | 3 | 2022 | 309 | 0.470 |
Why?
|
Death | 5 | 2023 | 685 | 0.460 |
Why?
|
SEER Program | 7 | 2021 | 1443 | 0.460 |
Why?
|
CA-125 Antigen | 1 | 2016 | 282 | 0.460 |
Why?
|
Sexual Dysfunction, Physiological | 1 | 2017 | 364 | 0.440 |
Why?
|
Insurance Coverage | 4 | 2021 | 1945 | 0.440 |
Why?
|
Aged | 49 | 2024 | 171343 | 0.430 |
Why?
|
Physician-Patient Relations | 7 | 2024 | 3266 | 0.430 |
Why?
|
National Institutes of Health (U.S.) | 1 | 2017 | 792 | 0.430 |
Why?
|
Patient Compliance | 2 | 2020 | 2694 | 0.420 |
Why?
|
Exercise | 2 | 2021 | 5945 | 0.420 |
Why?
|
Chemotherapy, Adjuvant | 6 | 2019 | 3552 | 0.410 |
Why?
|
Research Support as Topic | 1 | 2017 | 697 | 0.410 |
Why?
|
Workload | 1 | 2018 | 849 | 0.390 |
Why?
|
Middle Aged | 50 | 2024 | 223257 | 0.380 |
Why?
|
Physical Therapy Modalities | 2 | 2016 | 533 | 0.380 |
Why?
|
Acculturation | 1 | 2013 | 179 | 0.380 |
Why?
|
Patient Protection and Affordable Care Act | 3 | 2021 | 1188 | 0.370 |
Why?
|
Public Health Administration | 1 | 2013 | 242 | 0.370 |
Why?
|
Athletic Injuries | 1 | 2021 | 1244 | 0.370 |
Why?
|
Practice Guidelines as Topic | 3 | 2020 | 7431 | 0.360 |
Why?
|
Spouses | 2 | 2024 | 286 | 0.350 |
Why?
|
Curriculum | 1 | 2024 | 3783 | 0.350 |
Why?
|
Adult | 38 | 2024 | 223307 | 0.330 |
Why?
|
Self Efficacy | 3 | 2024 | 643 | 0.330 |
Why?
|
Family | 3 | 2024 | 3209 | 0.330 |
Why?
|
Research | 1 | 2018 | 1977 | 0.320 |
Why?
|
Medical Oncology | 6 | 2023 | 2340 | 0.320 |
Why?
|
Health Services Accessibility | 3 | 2021 | 5514 | 0.320 |
Why?
|
Burnout, Professional | 1 | 2018 | 710 | 0.320 |
Why?
|
Reoperation | 1 | 2019 | 4325 | 0.310 |
Why?
|
Patient Education as Topic | 2 | 2021 | 2334 | 0.300 |
Why?
|
United States | 25 | 2023 | 72951 | 0.300 |
Why?
|
Attitude to Death | 6 | 2011 | 400 | 0.300 |
Why?
|
Qualitative Research | 6 | 2024 | 3138 | 0.300 |
Why?
|
Oncogenes | 1 | 2013 | 1231 | 0.290 |
Why?
|
Circumcision, Male | 1 | 2008 | 150 | 0.280 |
Why?
|
International Cooperation | 1 | 2013 | 1434 | 0.280 |
Why?
|
Medicare | 9 | 2023 | 6820 | 0.270 |
Why?
|
Osteoarthritis, Hip | 1 | 2011 | 409 | 0.270 |
Why?
|
Neoplasm Staging | 10 | 2021 | 11218 | 0.260 |
Why?
|
Tobacco Industry | 1 | 2007 | 138 | 0.260 |
Why?
|
Communication | 7 | 2024 | 3905 | 0.250 |
Why?
|
Clinical Pharmacy Information Systems | 1 | 2005 | 102 | 0.240 |
Why?
|
Adult Children | 2 | 2024 | 104 | 0.240 |
Why?
|
Antitrust Laws | 1 | 2004 | 8 | 0.240 |
Why?
|
Marketing | 1 | 2007 | 225 | 0.240 |
Why?
|
Nursing Care | 1 | 2005 | 66 | 0.240 |
Why?
|
Acquired Immunodeficiency Syndrome | 1 | 2013 | 2205 | 0.240 |
Why?
|
Abortion, Legal | 1 | 2006 | 121 | 0.240 |
Why?
|
Biomedical Research | 2 | 2018 | 3459 | 0.240 |
Why?
|
Medication Systems, Hospital | 1 | 2005 | 154 | 0.240 |
Why?
|
Psychotherapy, Group | 2 | 2019 | 417 | 0.230 |
Why?
|
Reagent Kits, Diagnostic | 1 | 2006 | 238 | 0.230 |
Why?
|
Students, Health Occupations | 1 | 2024 | 30 | 0.230 |
Why?
|
Prospective Studies | 13 | 2021 | 54871 | 0.220 |
Why?
|
Medically Uninsured | 2 | 2021 | 838 | 0.210 |
Why?
|
Relief Work | 1 | 2004 | 131 | 0.210 |
Why?
|
Life Expectancy | 4 | 2020 | 1249 | 0.210 |
Why?
|
Aged, 80 and over | 13 | 2022 | 59550 | 0.210 |
Why?
|
Program Evaluation | 2 | 2024 | 2504 | 0.210 |
Why?
|
Personnel Selection | 1 | 2004 | 201 | 0.200 |
Why?
|
Clinical Trials, Phase III as Topic | 2 | 2016 | 878 | 0.200 |
Why?
|
Salaries and Fringe Benefits | 1 | 2004 | 263 | 0.200 |
Why?
|
Early Detection of Cancer | 3 | 2023 | 3236 | 0.190 |
Why?
|
Adaptation, Psychological | 6 | 2024 | 2662 | 0.190 |
Why?
|
Stress, Psychological | 1 | 2017 | 4527 | 0.190 |
Why?
|
Male | 41 | 2024 | 364142 | 0.190 |
Why?
|
Hip Joint | 2 | 2020 | 1017 | 0.190 |
Why?
|
Drug Prescriptions | 2 | 2021 | 1663 | 0.190 |
Why?
|
Physician's Role | 2 | 2024 | 925 | 0.190 |
Why?
|
Quality of Health Care | 2 | 2016 | 4306 | 0.190 |
Why?
|
Patient Satisfaction | 4 | 2018 | 3485 | 0.190 |
Why?
|
Papillomaviridae | 2 | 2013 | 1139 | 0.190 |
Why?
|
Pyrimidinones | 2 | 2021 | 385 | 0.180 |
Why?
|
HIV Infections | 5 | 2015 | 17536 | 0.180 |
Why?
|
Colorectal Neoplasms | 2 | 2023 | 6962 | 0.180 |
Why?
|
Adenocarcinoma | 3 | 2018 | 6359 | 0.180 |
Why?
|
Viral Vaccines | 1 | 2006 | 596 | 0.180 |
Why?
|
Nurse's Role | 1 | 2022 | 187 | 0.180 |
Why?
|
Survival Rate | 7 | 2021 | 12825 | 0.180 |
Why?
|
Self Care | 1 | 2006 | 800 | 0.170 |
Why?
|
Mental Health | 3 | 2010 | 3270 | 0.170 |
Why?
|
DNA Mismatch Repair | 2 | 2022 | 432 | 0.170 |
Why?
|
Cross-Sectional Studies | 10 | 2024 | 26310 | 0.170 |
Why?
|
Ovarian Cysts | 1 | 2020 | 107 | 0.170 |
Why?
|
Delivery of Health Care | 1 | 2018 | 5368 | 0.170 |
Why?
|
Physicians | 1 | 2018 | 4591 | 0.170 |
Why?
|
Young Adult | 9 | 2024 | 59939 | 0.170 |
Why?
|
Public Health | 2 | 2017 | 2681 | 0.170 |
Why?
|
Shoulder | 1 | 2021 | 300 | 0.160 |
Why?
|
Combined Modality Therapy | 4 | 2021 | 8540 | 0.160 |
Why?
|
Attitude of Health Personnel | 3 | 2024 | 3927 | 0.160 |
Why?
|
Medication Errors | 1 | 2005 | 784 | 0.160 |
Why?
|
Proportional Hazards Models | 4 | 2018 | 12534 | 0.160 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 5 | 2022 | 11872 | 0.160 |
Why?
|
Insurance, Pharmaceutical Services | 1 | 2021 | 347 | 0.160 |
Why?
|
Spirituality | 4 | 2011 | 430 | 0.150 |
Why?
|
Carcinoma, Squamous Cell | 2 | 2013 | 4049 | 0.150 |
Why?
|
Medicare Part D | 1 | 2023 | 355 | 0.150 |
Why?
|
Lung Neoplasms | 3 | 2023 | 13485 | 0.150 |
Why?
|
Resistance Training | 1 | 2020 | 197 | 0.150 |
Why?
|
Leadership | 2 | 2018 | 1394 | 0.150 |
Why?
|
Delayed Diagnosis | 1 | 2022 | 454 | 0.150 |
Why?
|
Colorado | 1 | 2018 | 167 | 0.150 |
Why?
|
Yoga | 1 | 2021 | 277 | 0.140 |
Why?
|
Drug Evaluation, Preclinical | 1 | 2023 | 1331 | 0.140 |
Why?
|
Health Services Administration | 1 | 2018 | 63 | 0.140 |
Why?
|
Genes, Tumor Suppressor | 1 | 2022 | 1057 | 0.140 |
Why?
|
Fallopian Tube Neoplasms | 1 | 2020 | 329 | 0.140 |
Why?
|
Patients | 1 | 2023 | 908 | 0.140 |
Why?
|
Obesity | 3 | 2017 | 13090 | 0.140 |
Why?
|
Goals | 1 | 2022 | 717 | 0.140 |
Why?
|
Randomized Controlled Trials as Topic | 3 | 2021 | 10384 | 0.140 |
Why?
|
Cystadenocarcinoma, Serous | 1 | 2021 | 480 | 0.130 |
Why?
|
Health Expenditures | 3 | 2019 | 2390 | 0.130 |
Why?
|
Gastrointestinal Neoplasms | 1 | 2024 | 957 | 0.130 |
Why?
|
Psychotherapy, Brief | 1 | 2017 | 118 | 0.130 |
Why?
|
Drug Therapy | 1 | 2019 | 504 | 0.130 |
Why?
|
Time Factors | 6 | 2021 | 40149 | 0.130 |
Why?
|
Health Policy | 1 | 2008 | 2698 | 0.130 |
Why?
|
Intensive Care Units | 3 | 2016 | 3799 | 0.130 |
Why?
|
Peripheral Nervous System Diseases | 1 | 2021 | 713 | 0.120 |
Why?
|
Medicaid | 2 | 2021 | 2836 | 0.120 |
Why?
|
Papillomavirus Infections | 2 | 2013 | 1639 | 0.120 |
Why?
|
Budgets | 1 | 2017 | 233 | 0.120 |
Why?
|
Drug Utilization | 1 | 2021 | 1187 | 0.120 |
Why?
|
Leukemia | 1 | 2023 | 1521 | 0.120 |
Why?
|
Antineoplastic Agents, Phytogenic | 1 | 2019 | 616 | 0.120 |
Why?
|
Injections, Intraperitoneal | 1 | 2015 | 410 | 0.120 |
Why?
|
Infusions, Intravenous | 2 | 2020 | 2228 | 0.120 |
Why?
|
Disease-Free Survival | 3 | 2020 | 6850 | 0.120 |
Why?
|
Efficiency | 1 | 2018 | 479 | 0.120 |
Why?
|
Science | 1 | 2017 | 234 | 0.110 |
Why?
|
Propensity Score | 2 | 2019 | 1972 | 0.110 |
Why?
|
Cohort Studies | 9 | 2021 | 41710 | 0.110 |
Why?
|
South Africa | 3 | 2015 | 1875 | 0.110 |
Why?
|
Telephone | 1 | 2017 | 629 | 0.110 |
Why?
|
Job Satisfaction | 1 | 2018 | 548 | 0.110 |
Why?
|
Athletes | 1 | 2021 | 1161 | 0.110 |
Why?
|
Hospitalization | 3 | 2022 | 10823 | 0.110 |
Why?
|
Doxorubicin | 1 | 2020 | 2229 | 0.110 |
Why?
|
Comparative Effectiveness Research | 1 | 2019 | 713 | 0.110 |
Why?
|
Natural Language Processing | 2 | 2019 | 1203 | 0.110 |
Why?
|
Developing Countries | 1 | 2006 | 2913 | 0.110 |
Why?
|
Pyrazoles | 2 | 2021 | 2030 | 0.110 |
Why?
|
Efficiency, Organizational | 1 | 2018 | 695 | 0.110 |
Why?
|
Depression | 3 | 2024 | 8228 | 0.100 |
Why?
|
Withholding Treatment | 2 | 2015 | 619 | 0.100 |
Why?
|
Documentation | 1 | 2019 | 914 | 0.100 |
Why?
|
Genes, erbB-1 | 1 | 2013 | 161 | 0.100 |
Why?
|
Mutation | 3 | 2013 | 30213 | 0.100 |
Why?
|
Health Maintenance Organizations | 1 | 2015 | 656 | 0.100 |
Why?
|
MutS Homolog 2 Protein | 1 | 2012 | 200 | 0.100 |
Why?
|
Critical Care | 2 | 2016 | 2714 | 0.100 |
Why?
|
Uterine Neoplasms | 1 | 2021 | 1424 | 0.100 |
Why?
|
Single-Blind Method | 1 | 2016 | 1587 | 0.100 |
Why?
|
Prognosis | 5 | 2023 | 29948 | 0.100 |
Why?
|
Protein-Tyrosine Kinases | 1 | 2021 | 2426 | 0.100 |
Why?
|
Treatment Refusal | 1 | 2015 | 433 | 0.100 |
Why?
|
Cell Cycle Proteins | 2 | 2021 | 3439 | 0.090 |
Why?
|
Cancer Care Facilities | 2 | 2013 | 428 | 0.090 |
Why?
|
Survival Analysis | 5 | 2019 | 10100 | 0.090 |
Why?
|
Muscle Strength | 1 | 2016 | 639 | 0.090 |
Why?
|
Neoplasms, Germ Cell and Embryonal | 1 | 2016 | 497 | 0.090 |
Why?
|
Delphi Technique | 1 | 2015 | 892 | 0.090 |
Why?
|
Motivation | 1 | 2021 | 2020 | 0.090 |
Why?
|
Quality Indicators, Health Care | 1 | 2021 | 1804 | 0.090 |
Why?
|
Evidence-Based Practice | 1 | 2015 | 499 | 0.090 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 2 | 2023 | 5387 | 0.090 |
Why?
|
Religion and Medicine | 2 | 2009 | 161 | 0.090 |
Why?
|
Africa South of the Sahara | 1 | 2013 | 751 | 0.090 |
Why?
|
Fee-for-Service Plans | 1 | 2016 | 713 | 0.090 |
Why?
|
Fertility | 1 | 2015 | 770 | 0.090 |
Why?
|
Meningeal Neoplasms | 1 | 2019 | 1255 | 0.090 |
Why?
|
Anxiety Disorders | 2 | 2020 | 2744 | 0.090 |
Why?
|
Smoking | 1 | 2007 | 9077 | 0.090 |
Why?
|
Patient Acceptance of Health Care | 1 | 2024 | 3230 | 0.090 |
Why?
|
Mass Screening | 1 | 2006 | 5454 | 0.090 |
Why?
|
Vagina | 1 | 2015 | 849 | 0.080 |
Why?
|
Phosphatidylinositol 3-Kinases | 2 | 2022 | 2881 | 0.080 |
Why?
|
Phthalazines | 2 | 2022 | 397 | 0.080 |
Why?
|
Information Dissemination | 1 | 2018 | 1142 | 0.080 |
Why?
|
Faculty, Medical | 1 | 2018 | 1226 | 0.080 |
Why?
|
Advance Directives | 1 | 2011 | 249 | 0.080 |
Why?
|
Emergency Service, Hospital | 2 | 2021 | 7871 | 0.080 |
Why?
|
Adolescent | 7 | 2019 | 88904 | 0.080 |
Why?
|
Disclosure | 1 | 2015 | 755 | 0.080 |
Why?
|
Spiritual Therapies | 1 | 2009 | 60 | 0.080 |
Why?
|
Range of Motion, Articular | 1 | 2016 | 1597 | 0.080 |
Why?
|
Radiation Oncology | 1 | 2015 | 571 | 0.080 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 1 | 2013 | 904 | 0.080 |
Why?
|
Health Resources | 1 | 2015 | 951 | 0.080 |
Why?
|
Attitude to Health | 2 | 2015 | 2021 | 0.080 |
Why?
|
Neoplasms, Multiple Primary | 1 | 2012 | 594 | 0.080 |
Why?
|
Patient Selection | 1 | 2020 | 4252 | 0.080 |
Why?
|
DNA Mutational Analysis | 2 | 2013 | 4114 | 0.070 |
Why?
|
Kaplan-Meier Estimate | 4 | 2019 | 6512 | 0.070 |
Why?
|
Brachytherapy | 1 | 2015 | 1220 | 0.070 |
Why?
|
Referral and Consultation | 1 | 2020 | 3618 | 0.070 |
Why?
|
Length of Stay | 2 | 2014 | 6490 | 0.070 |
Why?
|
Multivariate Analysis | 2 | 2011 | 12064 | 0.070 |
Why?
|
Papillomavirus Vaccines | 1 | 2013 | 497 | 0.070 |
Why?
|
Reproducibility of Results | 3 | 2021 | 20144 | 0.070 |
Why?
|
History, 20th Century | 2 | 2004 | 2764 | 0.070 |
Why?
|
Patient Care Team | 1 | 2018 | 2519 | 0.070 |
Why?
|
Product Labeling | 1 | 2007 | 75 | 0.070 |
Why?
|
Africa | 1 | 2008 | 726 | 0.070 |
Why?
|
Gene Frequency | 1 | 2013 | 3624 | 0.070 |
Why?
|
Antibodies, Monoclonal | 2 | 2022 | 9244 | 0.070 |
Why?
|
Prevalence | 2 | 2021 | 15835 | 0.060 |
Why?
|
Computer User Training | 1 | 2005 | 19 | 0.060 |
Why?
|
Diagnosis, Differential | 1 | 2021 | 12985 | 0.060 |
Why?
|
Health Care Surveys | 1 | 2013 | 2425 | 0.060 |
Why?
|
Health Status | 1 | 2018 | 4087 | 0.060 |
Why?
|
Ligands | 2 | 2022 | 3275 | 0.060 |
Why?
|
Pain Measurement | 1 | 2016 | 3576 | 0.060 |
Why?
|
Consensus | 1 | 2015 | 3208 | 0.060 |
Why?
|
Education, Nursing, Continuing | 1 | 2005 | 69 | 0.060 |
Why?
|
Child of Impaired Parents | 1 | 2009 | 462 | 0.060 |
Why?
|
Severity of Illness Index | 3 | 2024 | 15908 | 0.060 |
Why?
|
Afghanistan | 1 | 2004 | 78 | 0.060 |
Why?
|
Taxes | 1 | 2007 | 219 | 0.060 |
Why?
|
Iraq | 1 | 2004 | 93 | 0.060 |
Why?
|
Hospitals, Military | 1 | 2004 | 62 | 0.060 |
Why?
|
Hospital Mortality | 2 | 2016 | 5343 | 0.060 |
Why?
|
Supreme Court Decisions | 1 | 2006 | 135 | 0.060 |
Why?
|
Endometriosis | 1 | 2012 | 868 | 0.060 |
Why?
|
Internship and Residency | 1 | 2004 | 5943 | 0.060 |
Why?
|
Device Approval | 1 | 2006 | 164 | 0.060 |
Why?
|
Resuscitation | 1 | 2008 | 681 | 0.060 |
Why?
|
Sex Factors | 1 | 2018 | 10619 | 0.060 |
Why?
|
Anti-Retroviral Agents | 1 | 2013 | 1787 | 0.060 |
Why?
|
Organizations | 1 | 2004 | 172 | 0.060 |
Why?
|
Breast Neoplasms | 2 | 2022 | 21162 | 0.050 |
Why?
|
Resuscitation Orders | 3 | 2011 | 271 | 0.050 |
Why?
|
False Positive Reactions | 1 | 2006 | 957 | 0.050 |
Why?
|
Logistic Models | 3 | 2018 | 13278 | 0.050 |
Why?
|
Disease Transmission, Infectious | 1 | 2008 | 560 | 0.050 |
Why?
|
Vaginal Smears | 1 | 2006 | 505 | 0.050 |
Why?
|
Electronic Health Records | 2 | 2018 | 4880 | 0.050 |
Why?
|
Hospital Information Systems | 1 | 2005 | 395 | 0.050 |
Why?
|
Treatment Outcome | 5 | 2022 | 65273 | 0.050 |
Why?
|
Ribose | 1 | 2022 | 63 | 0.050 |
Why?
|
Hematologic Neoplasms | 1 | 2014 | 1926 | 0.050 |
Why?
|
Diphosphates | 1 | 2022 | 89 | 0.050 |
Why?
|
Healthcare Disparities | 1 | 2018 | 3411 | 0.050 |
Why?
|
Homicide | 1 | 2004 | 294 | 0.050 |
Why?
|
Health Care Costs | 2 | 2019 | 3242 | 0.050 |
Why?
|
Commerce | 1 | 2007 | 614 | 0.050 |
Why?
|
Internationality | 1 | 2007 | 1006 | 0.050 |
Why?
|
Primary Prevention | 1 | 2008 | 1188 | 0.050 |
Why?
|
Saliva | 1 | 2006 | 852 | 0.050 |
Why?
|
China | 1 | 2007 | 2383 | 0.040 |
Why?
|
World Health Organization | 1 | 2007 | 1327 | 0.040 |
Why?
|
Genome, Human | 1 | 2013 | 4443 | 0.040 |
Why?
|
Abortion, Induced | 1 | 2006 | 471 | 0.040 |
Why?
|
Preventive Health Services | 1 | 2004 | 571 | 0.040 |
Why?
|
Decision Making | 3 | 2024 | 3951 | 0.040 |
Why?
|
Disease Progression | 2 | 2020 | 13640 | 0.040 |
Why?
|
Diamines | 1 | 2019 | 60 | 0.040 |
Why?
|
HSP90 Heat-Shock Proteins | 1 | 2021 | 422 | 0.040 |
Why?
|
Models, Statistical | 1 | 2013 | 5091 | 0.040 |
Why?
|
HIV Antibodies | 1 | 2006 | 1337 | 0.040 |
Why?
|
Genotype | 1 | 2013 | 13036 | 0.040 |
Why?
|
Genetic Predisposition to Disease | 1 | 2020 | 18075 | 0.040 |
Why?
|
Biomedical Technology | 1 | 2021 | 210 | 0.040 |
Why?
|
Health Services for the Aged | 1 | 2021 | 264 | 0.040 |
Why?
|
History, 21st Century | 1 | 2004 | 1574 | 0.040 |
Why?
|
Longitudinal Studies | 3 | 2010 | 14762 | 0.040 |
Why?
|
Receptor, erbB-2 | 2 | 2022 | 2597 | 0.040 |
Why?
|
Religion and Psychology | 2 | 2010 | 180 | 0.040 |
Why?
|
Politics | 1 | 2004 | 821 | 0.040 |
Why?
|
MAP Kinase Kinase Kinases | 1 | 2019 | 252 | 0.040 |
Why?
|
Retrospective Studies | 4 | 2019 | 81635 | 0.040 |
Why?
|
Genes, BRCA1 | 1 | 2021 | 753 | 0.030 |
Why?
|
Cost Control | 1 | 2019 | 628 | 0.030 |
Why?
|
Hospitals | 1 | 2010 | 3888 | 0.030 |
Why?
|
Syndrome | 1 | 2023 | 3271 | 0.030 |
Why?
|
Women's Health | 1 | 2006 | 2081 | 0.030 |
Why?
|
Administrative Personnel | 1 | 2018 | 185 | 0.030 |
Why?
|
Uncertainty | 1 | 2021 | 764 | 0.030 |
Why?
|
Models, Economic | 1 | 2019 | 719 | 0.030 |
Why?
|
Research Design | 2 | 2021 | 6207 | 0.030 |
Why?
|
Polyethylene Glycols | 1 | 2020 | 1189 | 0.030 |
Why?
|
Breast | 1 | 2023 | 1971 | 0.030 |
Why?
|
Receptors, Estrogen | 1 | 2022 | 2251 | 0.030 |
Why?
|
Asymptomatic Infections | 1 | 2015 | 136 | 0.030 |
Why?
|
Patient Care Planning | 1 | 2019 | 904 | 0.030 |
Why?
|
Core Binding Factor beta Subunit | 1 | 2013 | 42 | 0.030 |
Why?
|
Comorbidity | 2 | 2020 | 10580 | 0.030 |
Why?
|
Pyridones | 1 | 2019 | 818 | 0.030 |
Why?
|
E1A-Associated p300 Protein | 1 | 2013 | 125 | 0.030 |
Why?
|
Tomography, X-Ray Computed | 1 | 2016 | 20708 | 0.030 |
Why?
|
Research Personnel | 1 | 2018 | 589 | 0.030 |
Why?
|
Proto-Oncogene Proteins c-ets | 1 | 2013 | 313 | 0.030 |
Why?
|
Neoplasm Metastasis | 2 | 2013 | 4891 | 0.030 |
Why?
|
HLA-B Antigens | 1 | 2013 | 330 | 0.030 |
Why?
|
Drug Administration Schedule | 1 | 2020 | 4853 | 0.020 |
Why?
|
F-Box Proteins | 1 | 2013 | 199 | 0.020 |
Why?
|
Harm Reduction | 1 | 2013 | 143 | 0.020 |
Why?
|
Mitogen-Activated Protein Kinase 1 | 1 | 2013 | 478 | 0.020 |
Why?
|
Social Isolation | 1 | 2015 | 366 | 0.020 |
Why?
|
Virus Integration | 1 | 2013 | 307 | 0.020 |
Why?
|
Risk Factors | 3 | 2013 | 74881 | 0.020 |
Why?
|
Health Education | 1 | 2018 | 1060 | 0.020 |
Why?
|
NF-E2-Related Factor 2 | 1 | 2013 | 382 | 0.020 |
Why?
|
Marital Status | 1 | 2012 | 426 | 0.020 |
Why?
|
Sensitivity and Specificity | 1 | 2006 | 14652 | 0.020 |
Why?
|
Proto-Oncogene Proteins c-akt | 1 | 2019 | 2456 | 0.020 |
Why?
|
Databases, Factual | 2 | 2016 | 8066 | 0.020 |
Why?
|
Self Report | 1 | 2021 | 3771 | 0.020 |
Why?
|
Life Support Care | 1 | 2011 | 226 | 0.020 |
Why?
|
Sex Offenses | 1 | 2013 | 355 | 0.020 |
Why?
|
Health Knowledge, Attitudes, Practice | 2 | 2014 | 4056 | 0.020 |
Why?
|
Social Stigma | 1 | 2015 | 788 | 0.020 |
Why?
|
Family Characteristics | 1 | 2013 | 1002 | 0.020 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2020 | 10745 | 0.020 |
Why?
|
Pain | 1 | 2023 | 5098 | 0.020 |
Why?
|
Patient Transfer | 1 | 2014 | 789 | 0.020 |
Why?
|
Sexually Transmitted Diseases | 1 | 2013 | 668 | 0.020 |
Why?
|
Follow-Up Studies | 2 | 2021 | 39309 | 0.020 |
Why?
|
Continuity of Patient Care | 1 | 2014 | 1077 | 0.020 |
Why?
|
Sex Distribution | 1 | 2012 | 2274 | 0.020 |
Why?
|
Administration, Oral | 1 | 2015 | 4018 | 0.020 |
Why?
|
Age Distribution | 1 | 2012 | 2869 | 0.020 |
Why?
|
Diagnostic Imaging | 1 | 2020 | 3531 | 0.020 |
Why?
|
Child | 3 | 2013 | 80668 | 0.020 |
Why?
|
Heterozygote | 1 | 2012 | 2795 | 0.020 |
Why?
|
Drug Resistance, Neoplasm | 1 | 2020 | 5329 | 0.020 |
Why?
|
Social Support | 1 | 2015 | 2191 | 0.010 |
Why?
|
DNA Copy Number Variations | 1 | 2013 | 2045 | 0.010 |
Why?
|
Educational Status | 1 | 2012 | 2510 | 0.010 |
Why?
|
Quality Improvement | 1 | 2019 | 3850 | 0.010 |
Why?
|
Pregnancy | 1 | 2006 | 30237 | 0.010 |
Why?
|
Ubiquitin-Protein Ligases | 1 | 2013 | 1899 | 0.010 |
Why?
|
Probability | 1 | 2009 | 2476 | 0.010 |
Why?
|
Interviews as Topic | 1 | 2011 | 2741 | 0.010 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2013 | 2948 | 0.010 |
Why?
|
Home Care Services | 1 | 2009 | 659 | 0.010 |
Why?
|
Pandemics | 1 | 2021 | 8735 | 0.010 |
Why?
|
Proto-Oncogene Proteins | 1 | 2013 | 4522 | 0.010 |
Why?
|
Algorithms | 1 | 2021 | 14072 | 0.010 |
Why?
|
Boston | 1 | 2012 | 9346 | 0.010 |
Why?
|
Body Mass Index | 1 | 2017 | 13050 | 0.010 |
Why?
|
Incidence | 1 | 2016 | 21525 | 0.010 |
Why?
|
Genomics | 1 | 2013 | 5923 | 0.010 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2013 | 8621 | 0.010 |
Why?
|
Clinical Trials as Topic | 1 | 2013 | 8045 | 0.010 |
Why?
|
Odds Ratio | 1 | 2009 | 9661 | 0.010 |
Why?
|
Socioeconomic Factors | 1 | 2011 | 7841 | 0.010 |
Why?
|
Critical Illness | 1 | 2009 | 2750 | 0.010 |
Why?
|
DNA-Binding Proteins | 1 | 2013 | 9611 | 0.010 |
Why?
|
Signal Transduction | 1 | 2019 | 23619 | 0.010 |
Why?
|
Case-Control Studies | 1 | 2013 | 22248 | 0.010 |
Why?
|
Postoperative Complications | 1 | 2018 | 15831 | 0.010 |
Why?
|
Transcription Factors | 1 | 2013 | 12150 | 0.010 |
Why?
|
Predictive Value of Tests | 1 | 2009 | 15416 | 0.010 |
Why?
|
Risk Assessment | 1 | 2009 | 24295 | 0.000 |
Why?
|
Child, Preschool | 1 | 2009 | 42577 | 0.000 |
Why?
|